In short
This article discusses a clinical trial investigating the use of [18F]-MPPF, a radioactive tracer, in positron emission tomography (PET) imaging to study pain in Parkinson's disease (PD). The trial aims to explore the serotonin system's role in pain experienced by PD patients and compare brain activity between those with and without pain. This research could lead to a better understanding of pain mechanisms in Parkinson's disease and potentially improve treatment strategies.
At a glance
- Study Drug
- [18F]-MPPF (4-Fluoro-N-[2-[4-(2-Methoxyphenyl)Piperazin-1-Yl]Ethyl]-N-Pyridin-2-Ylbenzamide)
- Primary Objective
- Measure [18F]-MPPF distribution in the brain of Parkinson's disease patients with and without pain
- Secondary Objectives
- Assess relationship between [18F]-MPPF uptake and pain characteristics, compare pain-related functional networks, evaluate links between brain structure and pain parameters
- Participant Age Range
- 40-80 years
- Key Inclusion Criteria
- Parkinson's disease diagnosis, stable anti-parkinsonian treatment, MOCA score > 25, HADS-D score ≤ 11
- Key Exclusion Criteria
- Second-line therapy for PD, significant psychiatric history, contraindications to MRI, disabling dyskinesias
- Imaging Techniques
- PET with [18F]-MPPF, MRI (structural and functional)
- Maximum Dose
- 220 MBq/kg
- Administration Route
- Intravenous
What is 18F-MPPF?
18F-MPPF is a radioactive substance used in medical research, specifically for studying Parkinson's disease (PD) and pain associated with it. Its full chemical name is 4-fluoro-N-[2-[4-(2-methoxyphenyl)piperazin-1-yl]ethyl]-N-pyridin-2-ylbenzamide. This compound is not a medication, but rather a tool used in brain imaging studies.
Purpose of the Study
Researchers are using 18F-MPPF to better understand how pain works in Parkinson's disease. The main goal is to explore the role of the brain's serotonin system in PD-related pain. This study compares Parkinson's patients who experience pain with those who don't, to see if there are differences in how their brains process pain signals.
How 18F-MPPF Works
18F-MPPF is injected into the bloodstream and travels to the brain. It's designed to attach to specific receptors in the brain called serotonin 1A receptors. These receptors are involved in pain processing and mood regulation. By using a special imaging technique called Positron Emission Tomography (PET), doctors can see where 18F-MPPF accumulates in the brain, giving them information about the serotonin system's activity.
Eligibility Criteria
To participate in this study, patients must meet certain criteria:
- Have Parkinson's disease diagnosed according to specific medical criteria
- Be between 40 and 80 years old
- Have stable Parkinson's medication for at least 4 weeks
- Score above 25 on a cognitive test called MOCA (Montreal Cognitive Assessment)
- Not have severe depression (score 11 or less on a depression scale called HADS-D)
Some factors that would prevent participation include:
- Having had deep brain stimulation or using medication pumps for Parkinson's
- Significant psychiatric history
- Using certain antidepressants in the past 4 weeks
- Being unable to have an MRI scan
- Pregnancy or breastfeeding
These criteria help ensure the safety of participants and the reliability of the study results.
Study Objectives
The main objectives of this research are:
- To measure and compare the distribution of 18F-MPPF in the brains of Parkinson's patients with and without pain
- To understand how 18F-MPPF uptake relates to pain intensity and characteristics in patients who experience pain
- To examine how pain perception thresholds differ between the two groups
- To compare pain-related brain networks using functional MRI
- To investigate how brain structure relates to pain experiences in Parkinson's disease
These objectives aim to provide a comprehensive understanding of pain mechanisms in Parkinson's disease.
Potential Benefits
While this study doesn't directly treat pain, it could lead to significant advancements in understanding and treating pain in Parkinson's disease. By learning more about how the serotonin system is involved in pain processing, researchers may be able to develop new treatments or improve existing ones for Parkinson's patients suffering from pain.
Safety Considerations
18F-MPPF is given as an intravenous injection, meaning it's injected directly into a vein. The maximum dose used in this study is 220 MBq/kg (megabecquerels per kilogram). This is a measure of radioactivity, not weight. The exposure to radiation is carefully controlled and monitored to ensure participant safety.
It's important to note that this compound is used for research purposes only and is not a treatment. Participants will also undergo MRI scans, which do not involve radiation but require lying still in a confined space for some time.